靶向癌症中P2X受体的新药理学工具博士研究员
PhD Studentship: New pharmacological tools for targeting P2X receptors in cancer
原帖优先:申请材料、截止时间与资格以原帖和学校官方说明为准。
AI 中文速览
- 研究内容
- 本项目主要开展两类研究方向:一是在不同条件下表征癌细胞中重要P2X受体及其变体的表达;二是明确单独阻断或双重拮抗各种P2X受体对癌细胞生长和存活的益处。具体研究目标包括表征P2X7和P2X4受体在各类癌细胞系及条件下的剪接变体表达、利用CRISPR/Cas9基因编辑技术生成P2X7和P2X4敲除的癌细胞,以及在体外癌细胞存活和生长实验中测试P2X7/P2X4的双重拮抗剂。
- 申请条件
- 标准最低入学要求为药学、本硕连读药学(MPharm)、生物医学、生物医学科学或生物科学专业的2:1荣誉学士学位。
- 待遇
- 资助适用于英国申请者,包含3年的“本土”学费以及每年£20,409的博士生奖学金津贴(2027/28年度将根据商定的通货膨胀率进行调整)。
- 申请方式
- 原文未说明具体的申请方式与截止日期(仅提及项目处于理学院资助奖学金的竞争中)。
由 gemini-2.5-flash-lite 生成,博士岗判定置信度 100%。
岗位信息
- 截止
- (Europe/London) 剩 93 天
- 学科
- 药理、毒理与药剂学
- 合同类型
- 雇佣合同
- 原文薪资
- GBP 20,409 / 年(税前)
- 税后月薪(估)
- ¥12,800;房租后 ¥4,500
- 估算假设
- 单身、无子女、雇佣合同的粗略估算,以学校 offer 为准;扣除率 18%;汇率日期 2026-10-01
- 原帖发布
- 本站收录
- 内容更新
- 原帖导师候选(待核验)
- Dr Leanne Stokes
- 来源
- jobs.ac.uk(英国博士项目及学术招聘) · 最近核对 2026-11-22
- 详情核验
判定依据(原文摘录)
- 确认为博士培养机会
PhD Studentship: New pharmacological tools for targeting P2X receptors in cancer
- 英语国家/全英文项目,未要求当地语言
This project would suit a graduate from Biomedical Science or Pharmacology.
- 入学要求为2:1学位,属于硕士/荣誉学士要求,非仅学士即可
The standard minimum entry requirement is 2:1 in Pharmacology, MPharm, Biomedicine, Biomedical Science, Biological Sciences
原文
About the Project
Primary Supervisor - Dr Leanne Stokes
There is a growing literature documenting the exploitation of ion channels by cancer cells. P2X receptors are ligand-gated ion channels (P2X1-7) activated by the extracellular signalling molecule ATP. Concentrations of ATP are known to be high within tumour microenvironments potentially driving cellular adaptations and exploiting downstream signalling associated with P2X receptors. This project will undertake two main lines of investigation; i) to characterise the expression of important P2X receptors and their variants within cancer cells under different conditions, and ii) to determine the benefit of blocking various P2X receptors (either individually or through dual antagonism) to cancer cell growth and survival.
Aberrant splicing events are common within cancer and novel splice isoforms have the potential to be neo-antigens (e.g. targets for immunotherapy or markers for diagnostic/prognostic purposes). At least 18 splice variants of P2X7 have been described but very little is known about their expression levels and functionality. Nothing is known about P2X4 variants as yet. We will explore RNAseq data from public databases and together with quantitative PCR data, we will assemble this information. Our recent work has discovered compounds that can act as dual antagonists of P2X7 and P2X4 receptors and we will compare their efficacy to individual blockade of either P2X7 or P2X4.
The aims of the project are to 1) characterise splice variant expression of P2X7 and P2X4 receptors across a range of cancer cell lines and conditions, 2) generate P2X7 and P2X4-null cancer cells using CRISPR/Cas9 gene editing to further understand how these ion channels contribute to cancer cell biology, and 3) testing of dual antagonists of P2X7/P2X4 in in vitro cancer cell survival and growth assays. Skills developed: cell culture, molecular biology, gene editing and pharmacology plus transferable skills. This project would suit a graduate from Biomedical Science or Pharmacology.
Entry Requirements
The standard minimum entry requirement is 2:1 in Pharmacology, MPharm, Biomedicine, Biomedical Science, Biological Sciences
Mode of Study
Full-time
Start Date
1 October 2027
Additional Funding Information
This PhD project is in a competition for a Faculty of Science funded studentship. Funding is available to UK applicants and comprises ‘home’ tuition fees and an annual stipend for 3 years. The current UEA / institutional PhD stipend rate is £20,409 and will be subject to any agreed inflationary uplift for 2027/28.